Bictegravir

Bictegravir (INN; BIC) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Bictegravir (INN; BIC) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. In vitro and clinical results were presented by Gilead in the summer of 2016.

In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection. The combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in 2018 in Australia, the European Union and the United States and in 2019 in New Zealand and the United Kingdom; a generic version was approved by the Drugs Controller General of India in 2019. it is recommended as a first-line choice of antiretroviral therapy in several countries, including the European Union, the United Kingdom and the United States.

Bictegravir/lenacapavir is another combination drug made using bictegravir. It is in late stage development.

Synthesis

A couple of syntheses of bictegravir were recently reported. Below is one of them: The condensation of Meldrum's acid [2033-24-1] (1) with methoxyacetic acid [625-45-6] (2) in the presence of pivaloyl chloride gave rise to [343246-51-5] (3).

Treatment of this intermediate with 2,4,6-trifluorobenzylamine [214759-21-4] (4) and TFA gave β-ketoamide, 4-methoxy-3-oxo-N-(2,4,6-trifluorobenzyl)butanamide [1846582-16-8] (5). The reaction with DMF-DMA followed by condensation with 2,2-Dimethoxyethylamine [22483-09-6] (6) yielded vinylogous amide, PC154010209 (7).

Next, a cyclization reaction occurred upon treatment with dimethyl oxalate; [553-90-2 ] (8) and sodium methoxide giving rise to pyridone [1644158-10-0] (9) Acetal deprotection was followed by treatment with syn-aminopentanol, (1R,3S)-3-Aminocyclopentanol [1110772-05-8][124555-42-6] (10) under weakly basic conditions. This is an annulation reaction arriving at [1616340-94-3] (11).

Magnesium bromide mediated demethylation completed the synthesis of bictegravir (12).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370835882 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

19 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.